Jyong Biotech (NASDAQ:MENS) Stock Price Up 5.8% - What's Next?

Key Points

• Jyong Biotech (NASDAQ:MENS) shares rose by 5.8% during trading, reaching a high of $62.42, although this was accompanied by a 55% decline in trading volume compared to the average.
• Analyst ratings for Jyong Biotech are mixed, with Wall Street Zen assigning a "hold" rating, while Weiss Ratings maintained a "sell" rating, leading to a consensus rating of "Sell".
• The company's current 50-day simple moving average is $52.72, indicating potential price momentum in the stock's performance.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares were up 5.8% during trading on Tuesday . The company traded as high as $62.42 and last traded at $62.42. Approximately 117,661 shares traded hands during trading, a decline of 55% from the average daily volume of 262,080 shares. The stock had previously closed at $59.01.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on MENS shares. Wall Street Zen raised Jyong Biotech to a "hold" rating in a report on Monday, June 30th. Weiss Ratings reissued a "sell (e+)" rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of "Sell".

Jyong Biotech Stock Up 1.0%

The firm's 50-day simple moving average is $52.72.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.